|Bid||1.85 x 500|
|Day's Range||2.42 - 2.58|
|52 Week Range||0.83 - 3.24|
|PE Ratio (TTM)||-17.75|
|Earnings Date||Mar 6, 2017 - Mar 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.58|
Q1 2017 Antares Pharma Inc Earnings Call
Antares Pharma, Inc. (ATRS) announced first quarter results on May 10, 2017, posting lower than expected revenues and in-line earnings. First quarter revenues of $12.0 million declined 2.5% and compare to our $13.9 million estimate. Net loss of $0.03 per share matched our forecasts. Gross margin rose compared to 1Q:16 to 48.2% on the recognition of Otrexup deferred revenue, but fell sequentially on lower development revenue. The main difference between our revenue estimates and actuals was lower needle free and development revenues. Antares announced current status of QuickShot Testosterone (now also known as XYOSTED) which had its NDA accepted by the FDA generating an October 20, 2017 PDUFA date. A favorable nod by the agency could support an early 2018 launch of the testosterone injection product. A supplemental NDA was filed by Antares’ partner AMAG Pharmaceuticals for the Makena subcutaneous auto-injector in April. AMAG expects a 4Q:17 response from the FDA on this candidate and a subsequent launch. Progress on several of partner Teva’s products including generic epinephrine pen, teriparatide and exenatide is also a positive that should provide an increase in development revenue in 2017 and royalties in 2018.
EWING, N.J., May 16, 2017-- Antares Pharma, Inc. announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate delivered through the QuickShot ® auto ...